CMS FAQ on Stark mailing drugs violation (H.R. 5526) (S. 3458)
Misc pharmacy benefit managers (PBMs) issues relating to cancer care (general issues and multiple bills supporting)
Change Healthcare cyber attack
Pharmacy Benefit Manager Transparency Act (S. 127)
Misc. 340B Drug Discount Program issues (no specific bill number)
Hospital site-neutral payments
Medicare physician payment issues (no specific bill number)
Inflation Reduction Act (H.R. 5376)
Cancer drug shortages (no specific bill number)
Duration: January 1, 2012
to
present
General Issues: Medicare/Medicaid , Veterans , Health Issues
Spending: about $7,223,025 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), White House Office, Federal Trade Commission (FTC), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Veterans Affairs - Dept of (VA), Centers For Medicare and Medicaid Services (CMS), House of Representatives, Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 15.
Original Filing: 301549448.xml
Lobbying Issues
CMS FAQ on Stark mailing drugs violation (H.R. 5526) (S. 3458)
Misc pharmacy benefit managers (PBMs) issues relating to cancer care (general issues and multiple bills supporting)
Change Healthcare cyber attack
Pharmacy Benefit Manager Transparency Act (S. 127)
Misc. 340B Drug Discount Program issues (no specific bill number)
Hospital site-neutral payments
Medicare physician payment issues (no specific bill number)
Inflation Reduction Act (H.R. 5376)
Cancer drug shortages (no specific bill number)
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301538388.xml
Lobbying Issues
CMS FAQ on Stark mailing drugs violation (H.R. 5526) (s. 3458)
Misc pharmacy benefit managers (PBMs) issues relating to cancer care (general issues and multiple bills supporting)
Pharmacy Benefit Manager Transparency Act (S. 127)
Misc. 340B Drug Discount Program issues (no specific bill number)
Medicare physician payment issues (no specific bill number)
Inflation Reduction Act (H.R. 5376)
Cancer drug shortages (no specific bill number)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 21, 2023.
Original Filing: 301517027.xml
Lobbying Issues
CMS FAQ on Stark mailing drugs violation (H.R. 5526)
Misc pharmacy benefit managers (PBMs) issues relating to cancer care (general issues and multiple bills supporting)
Pharmacy Benefit Manager Transparency Act (S. 127)
Misc. 340B Drug Discount Program issues (no specific bill number)
Medicare physician payment issues (no specific bill number)
Inflation Reduction Act (H.R. 5376)
Timely Access to Critical Treatment Act (H.R. 4011)
Cancer drug shortages (no specific bill number)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 18, 2023.
Original Filing: 301480030.xml
Lobbying Issues
CMS FAQ on Stark mailing drugs violation (no bill number)
Misc pharmacy benefit managers (PBMs) issues relating to cancer care (general issues and multiple bills supporting)
Pharmacy Benefit Manager Transparency Act (S. 127)
Misc. 340B Drug Discount Program issues (no specific bill number)
Medicare physician payment issues (no specific bill number)
Enhancing Oncology Model (EOM) (no specific bill number)
Inflation Reduction Act (H.R. 5376)
Timely Access to Critical Treatment Act (H.R. 4011)
Cancer drug shortages (no specific bill number)
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 18, 2023.
Original Filing: 301454179.xml
Lobbying Issues
CMS FAQ on Stark mailing drugs violation (no bill number)
Misc pharmacy benefit managers (PBMs) issues relating to cancer care (no specific bill numbers)
Pharmacy Benefit Manager Transparency Act (S. 127)
Misc. 340B Drug Discount Program issues (no specific bill number)
Medicare physician payment issues (no specific bill number)
Enhancing Oncology Model (EOM) (no specific bill number)
Inflation Reduction Act (H.R. 5376)
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301432345.xml
Lobbying Issues
Inflation Reduction Act (H.R. 5376)
Misc pharmacy benefit manager (PBM) issues including DIR fees, delaying cancer patients' treatments, step therapy (no specific bills)
Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S. 1909)
Pharmacy Benefit Manager Transparency Act of 2022 (S. 4293)
TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours.
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Hospital and PBM consolidation.
CMS/CMMI payment models, including the OCM and OCF.
Inflation Reduction Act (HR 5376)
CMMI Oncology Payment Reform
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 24, 2022.
Original Filing: 301420716.xml
Lobbying Issues
Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill)
Misc pharmacy benefit manager (PBM) issues including DIR fees, delaying cancer patients' treatments, step therapy (no specific bills)
Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S 1909)
Pharmacy Benefit Manager Transparency Act of 2022 (S. 4293)
CMS proposed rule to reform PBM DIR fees
TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours.
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Hospital and PBM consolidation.
CMS/CMMI payment models, including the OCM and OCF.
Inflation Reduction Act (HR 5376)
CMMI Oncology Payment Reform
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 18, 2022.
Original Filing: 301383807.xml
Lobbying Issues
Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill)
Misc pharmacy benefit manager (PBM) issues including DIR fees, delaying cancer patients' treatments, step therapy (no specific bills)
Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S 1909)
Pharmacy Benefit Manager Transparency Act of 2022 (S. 4293)
CMS proposed rule to reform PBM DIR fees
TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours.
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Hospital and PBM consolidation.
CMS/CMMI payment models, including the OCM and OCF.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 19, 2022.
Original Filing: 301362015.xml
Lobbying Issues
Drug pricing aspects of the Build Back Better Act (HR 5376); House & Senate
Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill)
Misc pharmacy benefit manager (PBM) issues including DIR fees, delaying cancer patients' treatments, step therapy (no specific bills)
Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S 1909)
CMS proposed rule to reform PBM DIR fees
TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours.
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Hospital and PBM consolidation.
CMS/CMMI payment models, including the OCM and OCF.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 19, 2022.
Original Filing: 301330455.xml
Lobbying Issues
Drug pricing aspects of the Build Back Better Act (HR 5376); House & Senate
Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill)
Misc pharmacy benefit manager (PBM) issues including DIR fees and delaying cancer patients' treatments. (no specific bills)
Pharmacy DIR Reform To Reduce Senior Drug Costs Act (S 1909)
TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours.
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Hospital and PBM consolidation.
CMS/CMMI payment models, including the OCM and OCF.
Misc. provisions related to HR 3.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 31, 2021.
Original Filing: 301316675.xml
Lobbying Issues
Extend the moratorium on the application of the sequester cut to Medicare payments into 2022 (no specific bill)
Misc pharmacy benefit manager (PBM) issues including DIR fees and delaying cancer patients' treatments. (no specific bills)
TACT Act (HR 3258) to ensure cancer patients get their oral cancer drugs from PBMs within 72 hours.
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Hospital and PBM consolidation.
CMS/CMMI payment models, including the OCM and OCF.
Misc. provisions related to HR 3.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 21, 2021.
Original Filing: 301292420.xml
Lobbying Issues
Extend the moratorium on the application of the sequester cut to Medicare payments. (HR 1868 and as amended in the Senate)
Misc pharmacy benefit manager (PBM) issues including DIR fees and delaying cancer patients' treatments. (no specific bills)
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Hospital and PBM consolidation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
Community Oncology Alliance amended a lobbying report for in-house lobbying in Q22021 on July 21, 2021
Original Filing: 301292423.xml
Lobbying Issues
Extend the moratorium on the application of the sequester cut to Medicare payments. (HR 1868 and as amended in the Senate)
Misc pharmacy benefit manager (PBM) issues including DIR fees and delaying cancer patients' treatments. (no specific bills)
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Hospital and PBM consolidation.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301266702.xml
Lobbying Issues
Extend the moratorium on the application of the sequester cut to Medicare payments. (HR 1868 and as amended in the Senate)
Misc pharmacy benefit manager (PBM) issues including DIR fees and delaying cancer patients' treatments. (no specific bills)
Exposing hospitals not complying with HHS/CMS regulations to publish price transparency data. (no specific bills)
Working on 340B legislation that ensures patients in need receive the discounts, not DSH hospital systems.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 19, 2021.
Original Filing: 301234831.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B reimbursement.
Misc. issues dealing with pharmacy benefit managers (no bill).
Misc. issues dealing with COVID-19 and impact on cancer care.
Radiation Oncology Model.
Most Favored Nations Drug Pricing (Administration).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301219544.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B reimbursement.
Expanding telehealth application and reimbursement during the COVID-19 pandemic and beyond (no specific bill).
Stopping insurer prior authorization requirements during the COVID-19 pandemic (no bill).
Fixing the 340B drug discount program (no bill).
Misc. issues dealing with pharmacy benefit managers (no bill).
Misc. issues dealing with COVID-19 and impact on cancer care.
Radiation Oncology Model (HHS/CMS/CMMI)
Most Favored Nations Drug Pricing (Administration)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 22, 2020.
Original Filing: 301203371.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B reimbursement.
Expanding telehealth application and reimbursement during the COVID-19 pandemic and beyond (no specific bill).
Stopping insurer prior authorization requirements during the COVID-19 pandemic (no bill).
Fixing the 340B drug discount program (no bill).
Misc. issues dealing with pharmacy benefit managers (no bill).
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 18, 2020.
Original Filing: 301171983.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (HR748).
Expanding telehealth use (general and HR748).
Stopping insurer prior authorization requirements during the COVID-19 crisis (no bill).
Fixing the 340B drug discount program (no bill).
Misc. issues dealing with pharmacy benefit managers (no bill).
Step therapy and prior authorization (general).
Oncology Care Model (no bill).
Oncology Care First Model (no bill).
CMMI guardrail bill (HR5741).
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 17, 2020.
Original Filing: 301110766.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program (no bill).
Misc. issues dealing with pharmacy benefit managers (no bill).
Various drug pricing/costs (general and Prescription Drug Pricing Reduction Act of 2019; S2542).
Step therapy and prior authorization (general and Improving Seniors' Timely Access to Care Act of 2019; HR3107).
International Pricing Index Model (no bill).
Oncology Care Model (no bill).
Oncology Care First Model (no bill).
CMMI guardrail bill (no bill number; not introduced).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 19, 2019.
Original Filing: 301071910.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program (no bill).
Misc. issues dealing with pharmacy benefit managers (no bill).
Various drug pricing/costs (no bill).
Step therapy and prior authorization (no bill).
International Pricing Index Model (no bill).
Medicare coverage of CAR-T therapy (no bill).
Oncology Care Model (no bill).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 19, 2019.
Original Filing: 301050457.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program (no bill).
Misc. issues dealing with pharmacy benefit managers (no bill).
Various drug pricing/costs (no bill).
Step therapy and prior authorization (no bill).
International Pricing Index Model (no bill).
Medicare coverage of CAR-T therapy (no bill).
Oncology Care Model (no bill).
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 18, 2019.
Original Filing: 301029405.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program (no bill).
Moving Medicare Part B to Part D (no bill).
Misc. issues dealing with pharmacy benefit managers (no bill).
Various drug pricing/costs (no bill).
Step therapy and prior authorization (no bill).
International Pricing Index Model (no bill).
Medicare coverage of CAR-T therapy (no bill).
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 23, 2019.
Original Filing: 301018194.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program, including PAUSE Act (H.R. 4710), HELP Act (S. 2312, and
Ensuring the Value of the 340B Program Act (S. 2453) and other legislation in progress.
Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304).
Moving Medicare Part B to Part D (no bill).
Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act; H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act; and H.R. 5958 - Phair Pricing Act of 2018}.
Oncology Care Model (CMS/CMMI; no bill).
Various drug pricing/costs (no bill).
STEP therapy (no bill).
International Pricing Index Model (no bill)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 22, 2018.
Original Filing: 300995522.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program, including PAUSE Act (H.R. 4710), HELP Act (S. 2312, and
Ensuring the Value of the 340B Program Act (S. 2453) and other legislation in progress.
Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304).
Moving Medicare Part B to Part D (no bill).
Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act; H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act; and H.R. 5958 - Phair Pricing Act of 2018}.
Oncology Care Model (CMS/CMMI; no bill).
Various drug pricing/costs (no bill).
VA clawback of payments made to community oncology practices for treating veterans out of network.
STEP therapy (no bill).
Agencies Lobbied
U.S. Senate
Lobbying Issues
VA clawback of payments made to community oncology practices for treating veterans out of network (no bill).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 17, 2018.
Original Filing: 300965939.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program, including PAUSE Act (H.R. 4710), HELP Act (S. 2312, and
Ensuring the Value of the 340B Program Act (S. 2453) and other legislation in progress.
Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304).
Moving Medicare Part B to Part D (no bill).
Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act; H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act; and H.R. 5958 - Phair Pricing Act of 2018}.
Oncology Care Model (CMS/CMMI; no bill).
Drug pricing/costs (no bill).
VA clawback of payments made to community oncology practices for treating veterans out of network.
Agencies Lobbied
U.S. Senate
Lobbying Issues
VA clawback of payments made to community oncology practices for treating veterans out of network (no bill).
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 18, 2018.
Original Filing: 300947723.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program, including PAUSE Act (H.R. 4710, HELP Act (S. 2312, and
Ensuring the Value of the 340B Program Act (S. 2453)
Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304).
Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act}.
Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017.
Oncology Care Model (CMS/CMMI; no bill).
VA clawback of payments made to community oncology practices for treating veterans out of network.
Agencies Lobbied
U.S. Senate
Lobbying Issues
VA clawback of payments made to community oncology practices for treating veterans out of network (no bill).
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 20, 2018.
Original Filing: 300931596.xml
Lobbying Issues
Stopping the application of the sequester cut (current and new) to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program (no bill).
Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304).
Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act}.
Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017.
Oncology Care Model (CMS/CMMI; no bill).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 5, 2017.
Original Filing: 300901671.xml
Lobbying Issues
Application of the sequester cut to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program (no bill).
Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304).
Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act.
Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017.
Oncology Care Model (CMS/CMMI; no bill).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300894405.xml
Lobbying Issues
Application of the sequester cut to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program (no bill).
Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (H.R. 1920, S. 1304).
Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act.
Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017.
Oncology Care Model (CMS/CMMI; no bill).
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 19, 2017.
Original Filing: 300868705.xml
Lobbying Issues
Application of the sequester cut to Medicare Part B drug reimbursement (no bill).
Fixing the 340B drug discount program (no bill).
Fixing Medicare Part B drug reimbursement by eliminating the manufacturer-to-wholesaler prompt pay discount from the calculation of average sales price, the basis of Part B drug reimbursement (no bill).
Misc. issues dealing with pharmacy benefit managers and patient and pharmacy abuses (includes bills H.R 1316 - Prescription Drug Price Transparency Act and H.R.1038 - Improving Transparency and Accuracy in Medicare Part D Spending Act.
Medicare oncology payment reform (includes bills S. 463 - Cancer Care Payment Reform Act of 2017 and H.R. 1834 - Cancer Care Payment Reform Act of 2017.
Oncology Care Model (CMS/CMMI; no bill).
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 18, 2017.
Original Filing: 300848032.xml
Lobbying Issues
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934; S. 3211).
Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506).
Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care.
General discussion on the CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement. Specific legislation to stop the Medicare Part B Drug Payment Model (H.R. 5122).
Topics related to pharmaceutical benefit managers (PBMs)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300837137.xml
Lobbying Issues
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934; S. 3211).
Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506).
Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care.
General discussion on the CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement. Specific legislation to stop the Medicare Part B Drug Payment Model (H.R. 5122).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 15, 2016.
Original Filing: 300810020.xml
Lobbying Issues
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) and possible Senate companion bill.
Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416).
Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506).
Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care.
CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300803484.xml
Lobbying Issues
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) and possible Senate companion bill.
Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416).
Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506).
Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care.
CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300779440.xml
Lobbying Issues
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934)
Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416).
Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506).
Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 21, 2015.
Original Filing: 300765673.xml
Lobbying Issues
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934)
Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416).
Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506).
Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 21, 2015.
Original Filing: 300747093.xml
Lobbying Issues
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934)
Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416).
Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506).
Legislation to fix the sustainable growth rate (SGR) that is the basis for Medicare reimbursement of physician services (H.R. 2).
Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 19, 2015.
Original Filing: 300720952.xml
Lobbying Issues
Legislation to reform Medicare payment for oncology (no specific bill).
Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416).
Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506).
Legislation to fix the sustainable growth rate (SGR) that is the basis for Medicare reimbursement of physician services (H.R. 2).
Misc. discussions (no legislation) to address 340B drug discount program and site-of-service payment parity.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 15, 2015.
Original Filing: 300695970.xml
Lobbying Issues
Cancer Patient Protection Act of 2013 (HR 1425) to stop the Medicare sequester cut from being applied to payment for cancer drugs.
Correcting a technical problem with Medicare reimbursement for cancer drugs (inclusion of wholesaler-to-manufacturer prompt pay
discounts in the calculation of Medicare ASP-based reimbursement rates) (HR800 & S806).
General fix to the Medicare SGR-based physician reimbursement system.
Payment reform for cancer care.
Problems with the 340B drug discount program.
Payment parity between community cancer clinics and outpatient hospital departments.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 22, 2014.
Original Filing: 300689879.xml
Lobbying Issues
Cancer Patient Protection Act of 2013 (HR 1425) to stop the Medicare sequester cut from being applied to payment for cancer drugs.
Correcting a technical problem with Medicare reimbursement for cancer drugs (inclusion of wholesaler-to-manufacturer prompt pay discounts in the calculation of Medicare ASP-based reimbursement rates).
General fix to the Medicare SGR-based physician reimbursement system.
Payment reform for cancer care.
Problems with the 340B drug discount program.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 19, 2014.
Original Filing: 300663421.xml
Lobbying Issues
Passage of the Cancer Patient Protection Act of 2013 (H.R. 1416) to stop application of the Medicare sequester cut to cancer drugs; Passage of H.R. 800 & S. 806, identical bills to stop artificial reduction of Medicare reimbursement for cancer drugs due to inclusion of manufacturer-to-distributor prompt pay discounts in the calculation of reimbursement rates; House and Senate bills and legislative efforts to fix the Medicare reimbursement system based on the sustainable growth rate (SGR) and to reform the Medicare payment system; Passage of the Medicare Access to Cancer Treatment ACT (H.R 2869) to create site payment parity between community cancer clinics and outpatient hospitals for identical cancer care services.
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 21, 2014.
Original Filing: 300645526.xml
Lobbying Issues
Passage of the Cancer Patient Protection Act of 2013 (H.R. 1416) to stop application of the Medicare sequester cut to cancer drugs; Passage of H.R. 800 & S. 806, identical bills to stop artificial reduction of Medicare reimbursement for cancer drugs due to inclusion of manufacturer-to-distributor prompt pay discounts in the calculation of reimbursement rates; House and Senate bills and legislative efforts to fix the Medicare reimbursement system based on the sustainable growth rate (SGR) and to reform the Medicare payment system; Passage of the Medicare Access to Cancer Treatment ACT (H.R 2869) to create site payment parity between community cancer clinics and outpatient hospitals for identical cancer care services.
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 17, 2014.
Original Filing: 300619498.xml
Lobbying Issues
Cancer Patient Protection Act of 2003 (H.R. 1416) - Bill to stop the Medicare sequester cut to the cost of cancer drugs
Prompt Pay Legislation (H.R. 806) to fix a problem with cancer drug payments
SGR/Payment reform legislation in the Senate and House to fix the broken Medicare payment system
Cancer drug shortages
Agencies Lobbied
U.S. Senate
3rd Quarter, 2013
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 21, 2013.
Original Filing: 300603591.xml
Lobbying Issues
Cancer Patient Protection Act of 2013 - HR 1416
Prompt Pay Legislation - HR 800/S. 806
2014 Medicare Physician Fee Schedule
General - Drug Shortages
Agencies Lobbied
U.S. Senate
2nd Quarter, 2013
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 18, 2013.
Original Filing: 300576130.xml
Lobbying Issues
Advocacy for the Cancer Patient Protection Act of 2013 (HR1416) to add cosponsors and advance legislation.
Advocacy for HR 800 and S 806 to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
SGR payment reform (no legislation yet)
General Medicare Part B reimbursement issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 21, 2013.
Original Filing: 300558807.xml
Lobbying Issues
Medicare Part B Reimbursement
HR 800
Drug Shortages
SGR Payment Reform
Agencies Lobbied
U.S. Senate
4th Quarter, 2012
In Q4, Community Oncology Alliance had in-house lobbyists. The report was filed on Jan. 18, 2013.
Original Filing: 300532625.xml
Lobbying Issues
Patient Access to Drugs in Shortage Act (HR 6611)
Cancer Drug Shortages
Medicare SGR-based MD Reimbursement
HR 905 Medicare Prompt Pay Legislation
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Community Oncology Alliance had in-house lobbyists. The report was filed on Oct. 23, 2012.
Original Filing: 300521979.xml
Lobbying Issues
Cancer Drug Shortages
Medicare Part B Reimbursement
Physician Payment Reform
Agencies Lobbied
House of Representatives
2nd Quarter, 2012
In Q2, Community Oncology Alliance had in-house lobbyists. The report was filed on July 20, 2012.
Original Filing: 300493935.xml
Lobbying Issues
Cancer Drug Shortages
Medicare Part B Reimbursement
Physician Payment Reform
Agencies Lobbied
House of Representatives
1st Quarter, 2012
In Q1, Community Oncology Alliance had in-house lobbyists. The report was filed on April 20, 2012.
Original Filing: 300469416.xml
Lobbying Issues
Cancer Drug Shortages
Medicare Part B Reimbursement
Agencies Lobbied
House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...